TRBC1 and mature T-cell and NK-cell non-Hodgkin lymphoma: Nevertheless, TRBC1-targeting CAR-T cell therapy holds promise as a novel treatment for PTCL patients, and sustained remission may be achieved by improving CAR-T cell manufacturing (e.g., using allogeneic CAR-T cells or generating Tstem-like CAR-T cells).